ARVIS

ARVIS is a brand name for a series of cardiovascular medications developed by Nobel İlaç, primarily referring to fixed-dose combinations (FDCs) used to treat hypertension and dyslipidemia. The most comprehensive formulation, often marketed as ARVIS or ARVIS PLUS, is a triple combination of **amlodipine** (a calcium channel blocker), **rosuvastatin** (an HMG-CoA reductase inhibitor), and **valsartan** (an angiotensin II receptor blocker). This combination targets multiple cardiovascular risk factors simultaneously—blood pressure and lipid levels—to improve patient compliance and clinical outcomes through a single-pill regimen. In some markets, the name ARVIS may also refer to the dual combination of rosuvastatin and valsartan or to rosuvastatin monotherapy. Additionally, the name is shared with an augmented reality surgical guidance system (ARVIS®) used in orthopedic procedures, which is a medical device rather than a pharmaceutical agent.

Brand names

ARVISARVIS PLUS

Other names

amlodipine + rosuvastatin + valsartanrosuvastatin + valsartan